Merck, known as MSD outside of the United States and Canada, announced the European Commission has approved KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev (enfortumab vedotin-ejfv),… read more.
People with type 2 diabetes, heart disease or stroke who sleep well have better cognitive function and greater brain volume than people with the same conditions who sleep… read more.
The American Academy of Pediatrics has recommended a single intramuscular dose of vitamin K for newborns since 1961; however, in the last decade parents have increasingly elected to… read more.
Gilead Sciences, Inc. announced the detailed results from the Phase 3 IDEAL study, which demonstrated that the majority of participants living with PBC and treated with Livdelzi (seladelpar)… read more.
Johnson & Johnson announced results from three clinical analyses being presented during the Transcatheter Cardiovascular Therapeutics annual scientific symposium (TCT 2026) that report positive survival and patient outcomes… read more.
Ionis Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the indication extension for… read more.
HUTCHMED Limited announces positive results from the SANOVO Phase III trial in China. Orpathys (savolitinib) plus Tagrisso (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in… read more.
Johnson & Johnson announced that the FDA granted accelerated approval for RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) (subcutaneous injection, 160 mg/2,000 units per mL) as a single agent for… read more.
Astellas Pharma Inc. announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a New Drug Application (NDA) for Veoza… read more.
Emergency Medicine & Intensive Care
Neither local case mix, primary care provision, nor geography explain the large differences in hospital admission rates, ranging from less than 10% to more than 40%, from emergency… read more.
On 30 October 2026, the MHRA granted Dojolvi (triheptanoin), an oral liquid, conditional marketing authorisation to treat adult and paediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD)…. read more.
Ascendis Pharma announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with TransCon PTH (palopegteriparatide) for up to 5… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
